Kymera Therapeutics, Inc. KYMR
We take great care to ensure that the data presented and summarized in this overview for Kymera Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KYMR
View all-
Price T Rowe Associates Inc Baltimore, MD6.65MShares$270 Million0.04% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$244 Million3.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$210 Million7.77% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$199 Million28.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.75MShares$193 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA4.62MShares$188 Million0.04% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.5MShares$183 Million3.21% of portfolio
-
Black Rock Inc. New York, NY4.16MShares$169 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY2.97MShares$121 Million7.03% of portfolio
-
State Street Corp Boston, MA1.73MShares$70.3 Million0.0% of portfolio
Latest Institutional Activity in KYMR
Top Purchases
Top Sells
About KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Insider Transactions at KYMR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2024
|
Pamela Esposito |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$122,500
$49.0 P/Share
|
|
Dec 02
2024
|
Pamela Esposito |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$72,500
$29.55 P/Share
|
|
Sep 17
2024
|
Pamela Esposito |
SELL
Open market or private sale
|
Direct |
13,500
-73.52%
|
$648,000
$48.25 P/Share
|
|
Sep 17
2024
|
Pamela Esposito |
BUY
Exercise of conversion of derivative security
|
Direct |
13,500
+38.51%
|
$283,500
$21.87 P/Share
|
|
Aug 26
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$245,000
$49.1 P/Share
|
|
Aug 26
2024
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$50,000
$10.34 P/Share
|
|
Aug 20
2024
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
1
|
$46
$46.41 P/Share
|
|
Jul 16
2024
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
23,145
-10.27%
|
$1,041,525
$45.84 P/Share
|
|
Jul 16
2024
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,145
+16.3%
|
$46,290
$2.08 P/Share
|
|
Jul 15
2024
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
16,455
-14.67%
|
$740,475
$45.15 P/Share
|
|
Jul 15
2024
|
Jared Gollob Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,455
+12.79%
|
$32,910
$2.08 P/Share
|
|
Jul 09
2024
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
453,960
-1.87%
|
$16,796,520
$37.42 P/Share
|
|
Jul 01
2024
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,773
+2.81%
|
$93,865
$5.33 P/Share
|
|
Jun 27
2024
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+12.92%
|
$50,000
$2.08 P/Share
|
|
Jun 18
2024
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,413
+2.23%
|
$28,826
$2.08 P/Share
|
|
Jun 13
2024
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
10,200
-0.2%
|
$346,800
$34.98 P/Share
|
|
Jun 12
2024
|
Bruce Booth |
SELL
Open market or private sale
|
Indirect |
16,740
-0.17%
|
$585,900
$35.68 P/Share
|
|
Jun 07
2024
|
Joanna Horobin |
SELL
Open market or private sale
|
Direct |
8,500
-62.86%
|
$272,000
$32.88 P/Share
|
|
Jun 07
2024
|
Joanna Horobin |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+50.0%
|
$17,000
$2.08 P/Share
|
|
May 23
2024
|
Jeremy G Chadwick Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,575
-5.51%
|
$87,550
$34.99 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 198K shares |
|---|---|
| Open market or private purchase | 1 shares |
| Grant, award, or other acquisition | 90.8K shares |
| Open market or private sale | 1.46M shares |
|---|